News Article

AREVA Med acquires Macrocyclics, Inc.
Date: Oct 20, 2011
Source: ( click here to go to the source)

Featured firm in this article: Macrocyclics Inc of Plano, TX

Bethesda, Md., October 20, 2011 -- AREVA announced today that its nuclear medicine subsidiary, AREVA Med, has acquired Macrocyclics, Inc.

AREVA Med has developed innovative methods for producing lead-212 (212Pb), a rare radioactive isotope at the heart of promising research projects in nuclear medicine to develop new treatments against cancer.
Macrocyclics, based in Dallas, Texas, is the world leader in the production of chelators*, chemical agents that allow for the attachment of antibodies or proteins with radioactive isotopes for the development of powerful nuclear medical treat-ments targeted against aggressive types of cancer.

"This strategic acquisition allows us to be in a unique position in the global mar-ketplace. As a result, we can now offer new technology for attaching our isotope to antibodies targeting cancerous cells," said Patrick Bourdet, President and CEO of AREVA Med. "The experience and the outstanding know-how of the Macrocy-clics team, together with that of AREVA Med, will allow us to target more diseas┬Čes and accelerate the development of radioimmunotherapy treatments using AREVA's lead-212," added Bourdet.

"The acquisition of our company by AREVA Med comes at an ideal time when the therapeutic power of lead-212 has been proven. By bringing our expertise with chelators to the unique competencies of AREVA Med, we will develop new powerful and targeted treatments for patients. With AREVA Med's support, we will be able to offer an even broader range of services to our clients," added Garry Kiefer, CEO of Macrocyclics.

In January 2011, the U.S. Food & Drug Administration (FDA) gave AREVA Med authorization to begin clinical trials for a new medicine using lead-212 to combat particularly aggressive types of cancer.

The development of new treatments in nuclear medicine is limited by the availa-bility of isotopes. AREVA is building a new facility, the Maurice Tubiana Labora-tory, to produce large-scale quantities of medical-grade lead-212 in the Limousin region of France.

For more information, please visit:, and